Close Menu

mergers & acquisitions

Meridian Bioscience's acquisition of Bioline both provides Meridian a foothold in the PCR market and is expected to help drive future diagnostic development at the company.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.

Meridian has acquired the reagents maker, adding complementary products to its life science business. The firm also reported an 11 percent decline in Q3 revenues.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

Merck KGaA has formed a new division, called EMD Millipore, which had pro forma revenues of around $2.9 billion in 2009.

The deal adds to Evotec research funds and potential milestone payments associated with DeveloGen's discovery alliance with Boehringer Ingelheim on small molecules to treat type 2 diabetes.

Through the first half of 2010, 33 deals were either completed or announced, and some industry experts said that more deals are anticipated ahead.

The reduction in workforce is "intended to eliminate redundancies in the company's workforce as a result of the merger and to streamline the company's operations following the merger," Accelrys said in an SEC filing.

This is the third time in the past two weeks that Symyx has declined Certara's bid, saying it does not constitute a superior offer to Accelrys' offer to buy the firm.


New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.